Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totaling 3,994 shares, a decline of 52.1% from the May 31st total of 8,343 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average trading volume of 48,201 shares, the days-to-cover ratio is currently 0.1 days.

Eloxx Pharmaceuticals Stock Performance

Shares of NASDAQ:ELOX traded up $0.88 during midday trading on Tuesday, reaching $12.81. 21,924 shares of the company’s stock traded hands, compared to its average volume of 15,003. The stock has a market cap of $8.84 million, a P/E ratio of -0.84 and a beta of -1,932.88. Eloxx Pharmaceuticals has a 1 year low of $11.45 and a 1 year high of $17.50. The company has a fifty day simple moving average of $18.55.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.